| In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants T O'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley, J Mestan, ... Cancer research 65 (11), 4500-4505, 2005 | 1372 | 2005 |
| The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia RL Levine, M Loriaux, BJP Huntly, ML Loh, M Beran, E Stoffregen, ... Blood 106 (10), 3377-3379, 2005 | 502 | 2005 |
| Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib AS Corbin, PL Rosée, EP Stoffregen, BJ Druker, MW Deininger Blood 101 (11), 4611-4614, 2003 | 468 | 2003 |
| High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy SG Willis, T Lange, S Demehri, S Otto, L Crossman, D Niederwieser, ... Blood 106 (6), 2128-2137, 2005 | 408 | 2005 |
| Activating alleles of JAK3 in acute megakaryoblastic leukemia DK Walters, T Mercher, TL Gu, T O'Hare, JW Tyner, M Loriaux, VL Goss, ... Cancer cell 10 (1), 65-75, 2006 | 368 | 2006 |
| Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) P La Rosée, AS Corbin, EP Stoffregen, MW Deininger, BJ Druker Cancer research 62 (24), 7149-7153, 2002 | 310 | 2002 |
| Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML T O'Hare, R Pollock, EP Stoffregen, JA Keats, OM Abdullah, EM Moseson, ... Blood 104 (8), 2532-2539, 2004 | 268 | 2004 |
| Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib IJ Griswold, M MacPartlin, T Bumm, VL Goss, T O'Hare, KA Lee, ... Molecular and cellular biology 26 (16), 6082-6093, 2006 | 235 | 2006 |
| In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines P La Rosée, K Johnson, AS Corbin, EP Stoffregen, EM Moseson, S Willis, ... Blood 103 (1), 208-215, 2004 | 140 | 2004 |
| Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib T O'Hare, DK Walters, EP Stoffregen, DW Sherbenou, MC Heinrich, ... Clinical cancer research 11 (19), 6987-6993, 2005 | 127 | 2005 |
| High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia MM Loriaux, RL Levine, JW Tyner, S Fröhling, C Scholl, EP Stoffregen, ... Blood, The Journal of the American Society of Hematology 111 (9), 4788-4796, 2008 | 108 | 2008 |
| Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes DK Walters, VL Goss, EP Stoffregen, TL Gu, K Lee, J Nardone, ... Leukemia research 30 (9), 1097-1104, 2006 | 75 | 2006 |
| RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518 DK Walters, EP Stoffregen, MC Heinrich, MW Deininger, BJ Druker Blood 105 (7), 2952-2954, 2005 | 50 | 2005 |
| Asynchronous Replication, Mono-Allelic Expression, and Long Range Cis-Effects of ASAR6 N Donley, EP Stoffregen, L Smith, C Montagna, MJ Thayer PLoS genetics 9 (4), e1003423, 2013 | 49 | 2013 |
| An autosomal locus that controls chromosome-wide replication timing and mono-allelic expression EP Stoffregen, N Donley, D Stauffer, L Smith, MJ Thayer Human molecular genetics 20 (12), 2366-2378, 2011 | 48 | 2011 |
| No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec™/Glivec®) P La Rosee, L Shen, EP Stoffregen, M Deininger, BJ Druker The Hematology Journal 4 (6), 413-419, 2003 | 31 | 2003 |
| A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib LC Crossman, T O'hare, T Lange, SG Willis, EP Stoffregen, AS Corbin, ... Leukemia 19 (11), 1859-1862, 2005 | 25 | 2005 |
| Sources and Structures of Mitotic Crossovers That Arise When BLM Helicase Is Absent in Drosophila MC LaFave, SL Andersen, EP Stoffregen, J Korda Holsclaw, KP Kohl, ... Genetics 196 (1), 107-118, 2014 | 18 | 2014 |
| Blm helicase facilitates rapid replication of repetitive DNA sequences in early Drosophila development JM Ruchert, MM Brady, S McMahan, KJ Lacey, LC Latta, J Sekelsky, ... Genetics 220 (1), iyab169, 2022 | 7 | 2022 |
| Potent inhibition of imatinib-resistant variants of Ber-Abl by a novel dual selective Src/Abl kinase inhibitor AP23464: Implications for CML therapy. T O'Hare, EP Stoffregen, OM Abdullah, MW Deininger, VM Rivera, H Tang, ... Blood 102 (11), 20A-20A, 2003 | 4 | 2003 |
